Full Text View
Tabular View
No Study Results Posted
Related Studies
12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.
This study has been completed.
Study NCT00046150   Information provided by Sanofi-Aventis
First Received: September 20, 2002   Last Updated: June 18, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diabetes, Type I
Additional conditions recognized in this trial
Diabetes Mellitus
Diabetes Mellitus, Type 1
More general conditions related to this trial
Autoimmune Diseases
Endocrine System Diseases
Glucose Metabolism Disorders
Immune System Diseases
Metabolic Diseases
Interventions listed in this trial
Insulin glulisine (HMR1964)
Additional drug interventions recognized in this trial
Insulin
Insulin glulisine
Insulin, Asp(B28)-
More general drug interventions related to this trial
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Sanofi-Aventis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services